Natera Inc.
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
Summary
Natera, Inc. announced preliminary fourth quarter and full year 2023 revenues on January 9, 2024. The company expects total revenues of approximately $300 million for the fourth quarter, a 38% increase from the same period in 2022. For the full year 2023, Natera anticipates total revenues of approximately $1.07 billion, a 30% increase from 2022. These results are approximately $20 million above the top end of their guidance. Further details and final financial results will be disclosed during their earnings call in February 2024.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement